MedPath

Losartan

Generic Name
Losartan
Brand Names
Hyzaar, Cozaar
Drug Type
Small Molecule
Chemical Formula
C22H23ClN6O
CAS Number
114798-26-4
Unique Ingredient Identifier
JMS50MPO89
Background

Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide. Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995.

Indication

Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension. Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).

Associated Conditions
Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke

Losartan for the Treatment of Pediatric NAFLD

Phase 2
Terminated
Conditions
NAFLD - Nonalcoholic Fatty Liver Disease
Interventions
First Posted Date
2018-03-15
Last Posted Date
2021-10-21
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
83
Registration Number
NCT03467217
Locations
🇺🇸

Emory University, Atlanta, Georgia, United States

🇺🇸

Northwestern Univ-Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

🇺🇸

University of Washington, Seattle, Washington, United States

and more 7 locations

A Bioequivalence Study of Losartan Potassium Tablets (Containing Losartan Potassium 100 mg) in Normal, Healthy, Adults Under Fasting Conditions

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2018-03-09
Last Posted Date
2018-11-02
Lead Sponsor
Pharmtechnology LLC
Target Recruit Count
66
Registration Number
NCT03459911
Locations
🇮🇳

Clinical Unit, Reliance Life Sciences Pvt. Ltd., Mumbai, Maharashtra, India

N-of-1 Trials In Children With Hypertension

Phase 4
Completed
Conditions
Pediatric Hypertension
Interventions
First Posted Date
2018-03-09
Last Posted Date
2022-09-09
Lead Sponsor
The University of Texas Health Science Center, Houston
Target Recruit Count
49
Registration Number
NCT03461003
Locations
🇺🇸

The University of Texas Health Science Center at Houston, Houston, Texas, United States

Effect of Losartan in Cystic Fibrosis (CF)-NIH Grant #133240

Early Phase 1
Active, not recruiting
Conditions
Cystic Fibrosis
Interventions
First Posted Date
2018-02-19
Last Posted Date
2024-12-06
Lead Sponsor
University of Kansas Medical Center
Target Recruit Count
16
Registration Number
NCT03435939
Locations
🇺🇸

University of Kansas Medical Center, Kansas City, Kansas, United States

The Effect of Losartan on Emotional Processing in Healthy Volunteers

Not Applicable
Completed
Conditions
Healthy Volunteers
Interventions
Other: Placebo
First Posted Date
2018-02-15
Last Posted Date
2018-02-19
Lead Sponsor
University of Oxford
Target Recruit Count
30
Registration Number
NCT03434054

Losartan and Emotion Processing

Not Applicable
Conditions
Healthy
Interventions
Drug: Placebo Oral Tablet
First Posted Date
2018-01-11
Last Posted Date
2018-06-06
Lead Sponsor
University of Electronic Science and Technology of China
Target Recruit Count
70
Registration Number
NCT03396523
Locations
🇨🇳

University of Electronic Science and Technology of China, Chengdu, Sichuan, China

Beginning of Effective and Safe Treatment in Immunoglobulin A-1 Nephropathy-1

Phase 3
Conditions
Glomerulonephritis, Immunoglobulin A (IgA)
Interventions
Drug: Placebo group
First Posted Date
2017-11-30
Last Posted Date
2017-11-30
Lead Sponsor
Ewha Womans University
Target Recruit Count
174
Registration Number
NCT03357653

AT1R Blockade and Periodic Breathing During Sleep in Hypoxia

Phase 4
Completed
Conditions
Sleep Disordered Breathing
Hypoxia
Respiration; Sleep Disorder
Chemoreceptor Apnea
Interventions
Other: Hyperoxic Hypercapnic Ventilatory Response Test
Other: Hypoxic Hypercapnic Ventilatory Response Test
Other: Repeated Hypoxic Apneas
Other: Hypoxic Sleep Study
Drug: Placebo
First Posted Date
2017-11-08
Last Posted Date
2020-09-04
Lead Sponsor
University of British Columbia
Target Recruit Count
14
Registration Number
NCT03335904
Locations
🇨🇦

University of British Columbia, Kelowna, British Columbia, Canada

ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension

Phase 2
Active, not recruiting
Conditions
Sedentary Lifestyle
Aging
Hypertension
Interventions
Behavioral: Aerobic exercise
First Posted Date
2017-09-28
Last Posted Date
2024-05-08
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
213
Registration Number
NCT03295734
Locations
🇺🇸

UAB Center for Exercise Medicine, Birmingham, Alabama, United States

🇺🇸

Translational Research Institute, Orlando, Florida, United States

A Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension

Phase 4
Completed
Conditions
Hypertension
Pharmacogenetics
Interventions
First Posted Date
2017-09-08
Last Posted Date
2017-09-11
Lead Sponsor
Helsinki University Central Hospital
Target Recruit Count
233
Registration Number
NCT03276598
Locations
🇫🇮

Helsinki University Central Hospital, Helsinki, Finland

© Copyright 2025. All Rights Reserved by MedPath